Rob's Lobs

[Rob]

Columbus Day Data Dump?

So, is the Huge One going to come down from the mountain today and bless us all with the Columbus Day Data Dump?

[Rob]

Definitely symetrical. Should be bullish but I don't think so for today.

This lob was not intended to suggest anyone buy IIIN today, or even to predict it's a future winner. But I posted it as one to keep on the radar. Wouldn't you love to have bought it at the beginning of 06?

Edit: Just checked. They report Q4 earnings at 8:30 a.m. on Oct. 20 (same day of options expiration). For 420 bucks you could play a straddle with one contract on each side of the $20 strike.

Oct. calls & puts

[skiracer]

Current P/E is around 13.

The triangle is actually pretty symmetrical if you plot it on a log scale chart.

Financials

Definitely symetrical. Should be bullish but I don't think so for today.

[Rob]

Will YouTube Become GoogTube?

It is rumored that .... well, just read it for yourself:

Completely Unsubstantiated Google/YouTube Rumor

[Rob]

Insteel Industies, Inc. (IIIN)

Current P/E is around 13.

The triangle is actually pretty symmetrical if you plot it on a log scale chart.

Financials

[New-born baby]

New-born,
Cramer has said 500 numerous times lately.

--------------billyjoe

Oh.
I don't watch/listen to Cramer. My ignorance.

[billyjoe]

Rob,
GOOG is right up against its range bound resistance: $416. If GOOG pulls back here, well, that has been the normal thing of late. IF GOOG busts out from here, a couple days sustained above $416 turns that resistance right into support, and you are sitting pretty.

New-born,
Cramer has said 500 numerous times lately.

--------------billyjoe

[New-born baby]

Goog

Rob,
GOOG is right up against its range bound resistance: $416. If GOOG pulls back here, well, that has been the normal thing of late. IF GOOG busts out from here, a couple days sustained above $416 turns that resistance right into support, and you are sitting pretty.

[spikefader]

Spike, I've composed two different replies to your note, neither of which I chose to post, because I don't want to start another fight. Bottom line: if you're so convinced IMCL is going down, just let me know at what price you're shorting it.

What a mature and polite reply this is! SssSss.

[Rob]

Rob, very nice plan as a 10-11% profit is very nice.

Yes, Runner, I agree. And as it so happens, that stop is resetting higher and higher as we speak.

My current EBAY long position is close to +16%, so I set a 5% trailing stop under it. I have mixed feelings about doing that, but, as the saying goes, "better safe than sorry."

Rob, very nice plan as a 10-11% profit is very nice.

[Rob]

My current EBAY long position is close to +16%, so I set a 5% trailing stop under it. I have mixed feelings about doing that, but, as the saying goes, "better safe than sorry."

[Rob]

Erbitux: Promising Results in First Line Treatment for Metastatic Colorectal Cancer

From http://tinyurl.com/oc8b8 (emphasis added):

Adding Cetuximab (Erbitux) to First-Line Chemotherapy Boosts Results in Metastatic Colorectal Cancer: Presented at ESMO
By Jill Stein

ISTANBUL, TURKEY -- October 3, 2006 -- Cetuximab (Erbitux) appears to improve tumor response and disease control in first-line treatment of metastatic colorectal cancer (mCRC) when added to 2 different chemotherapy regimens.

Volker Heinemann, MD, Director of Klinikhum Grosshadern, Medizinishe Klinik III, Munich, Germany, presented updated interim results of the ongoing trial during an oral session on October 2nd at the 31st European Society of Medical Oncology (ESMO) Congress.

The study randomized 84 patients with mCRC and a median Karnofsky Performance Status of more than 70%, cetuximab -- epidermal growth factor receptor (EGFR)-targeting antibody -- in combination with either XELIRI or XELOX.

The XELIRI regimen consisted of capecitabine 2 x 800 mg/m2 orally on days 1 to 14 plus irinotecan 200 mg/m2 intravenously on day 1. The XELOX regimen involved oral capecitabine 2 x 1000 mg/m2 on days 1 to 14 plus IV oxaliplatin 130 mg/m2 on day 1.

In both treatment arms, IV cetuximab was given at a dose of 400 mg/m2 on day 1 of the first 3-week cycle followed by 250 mg/m2 during each subsequent cycle.

The primary endpoint of objective response rate was 42% in the XELIRI arm and 65.5% in the XELOX arm. Disease control rates were 90.9% and 93.1%, respectively.

"Both treatments were highly effective and the disease control rates were high," Dr. Heinemann commented.

Without cetuximab, these regimens would be more likely to show disease control rates in the region of 40% and 50%, respectively, according to previous studies, he said.

"There was more hematological toxicity in the XELIRI arm but more neurotoxicity in the oxaliplatin arm, as would be expected," he added.

"These are promising results in the first-line setting," Dr. Heinemann concluded. The trial is continuing to recruit patients until November, 2006.

[Presentation title: Cetuximab Plus Capecitabine/Irinotecan (XELIRI) versus Cetuximab Plus Capecitabine/Oxaliplatin (XELOX) as First-Line Treatment for Patients With Metastatic Colorectal Cancer (CRC): A Randomized Trial of the AIO CRC Study Group. Abstract 327O]

[New-born baby]

Just broke it. We are now in record high territory.

IF it can hold it, we are going to rocket!

[Rob]

The all-time intraday high on the DOW is 11,750.28.

It just came 0.68 shy of hitting it a few minutes ago.

Just broke it. We are now in record high territory.